Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,098 | 0,137 | 29.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CANTARGIA Aktie jetzt für 0€ handeln | |||||
17.06. | Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans | 255 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million... ► Artikel lesen | |
17.06. | Cantargia Q1 2025 slides: CAN10 advances amid funding challenges | 3 | Investing.com | ||
11.06. | Cantargia's Nadunolimab Aantibody Awarded US FDA Fast Track Designation | 648 | ACCESS Newswire | Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development... ► Artikel lesen | |
11.06. | Cantargia AB: Cantargia's nadunolimab antibody awarded US FDA Fast Track Designation | 306 | GlobeNewswire (Europe) | Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development... ► Artikel lesen | |
19.05. | Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation | 205 | ACCESS Newswire | IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,... ► Artikel lesen | |
15.05. | Bulletin from the Annual General Meeting in Cantargia AB | 271 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge... ► Artikel lesen | |
13.05. | Cantargia Publishes Interim Report for the First Quarter of 2025 | 403 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The first... ► Artikel lesen | |
12.05. | Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2 | 210 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model... ► Artikel lesen | |
06.05. | Cantargia's Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors | 234 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA)Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications... ► Artikel lesen | |
29.04. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2025 | 217 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025... ► Artikel lesen | |
29.04. | Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10 | 191 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA)Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets... ► Artikel lesen | |
28.04. | Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression | 104 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 28, 2025 / Cantargia (STO:CANTA)Preclinical data shows IL1 family signals mediate systemic immune suppression.Blocking IL1RAP can overcome resistance to immune therapy... ► Artikel lesen | |
25.04. | Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate at a Major Cancer Conference | 412 | ACCESS Newswire | Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment... ► Artikel lesen | |
25.04. | Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy at AACR | 352 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA)Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention... ► Artikel lesen | |
11.04. | Cantargia Publishes Annual Report 2024 | 294 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The... ► Artikel lesen | |
11.04. | Notice of Annual General Meeting in Cantargia AB | 269 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon... ► Artikel lesen | |
01.04. | Cantargia appoints Morten Lind Jensen as Chief Medical Officer | 234 | ACCESS Newswire | LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief... ► Artikel lesen | |
25.03. | Cantargia Publishes An Abstract On Parallel Anti-Tumor Activity And Reduction Of Chemotherapy-Induced Neuropathy With Nadunolimab | 468 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA)Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinical... ► Artikel lesen | |
25.03. | Cantargia Presents Promising Preclinical Results on a Novel IL1RAP-Targeting Antibody-Drug Conjugate at AACR 2025 | 322 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the development... ► Artikel lesen | |
13.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 510 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 13, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participate... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 444,00 | -0,22 % | Bayer, Regeneron get EU nod for Eylea's label extension | ||
BRAIN BIOTECH | 1,860 | -3,38 % | BRAIN Biotech: Wann kommt die Trendwende bei den Biokatalysatoren? | Die BRAIN Biotech AG (DE0005203947) kämpft mit einem schwierigen Marktumfeld. Im ersten Halbjahr 2024/25 ging der Umsatz um 7,2 Prozent auf 25,2 Millionen Euro zurück. Das Unternehmen spürt die Auswirkungen... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
CARDIOL THERAPEUTICS | 1,304 | +8,49 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
BURCON NUTRASCIENCE | 2,635 | +1,54 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2025 Results and Reviews Operations | Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
CSL | 131,64 | +0,41 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
MANNKIND | 3,214 | +0,19 % | MannKind Corp. Q1 Sales Increase | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) released a profit for first quarter of $13.16 millionThe company's earnings totaled $13.16 million, or $0.04 per share. This compares with $10.63... ► Artikel lesen | |
OCULAR THERAPEUTIX | 8,198 | +4,04 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
OXFORD NANOPORE TECHNOLOGIES | 1,558 | -2,26 % | Volta Labs Inc.: Volta Labs Expands Long-Read Sequencing Capabilities with Automated Oxford Nanopore Library Prep App on Callisto | BOSTON, June 12, 2025 /PRNewswire/ -- Volta Labs, a genomics applications company, today announced the launch of its Library Prep App for Oxford Nanopore LSK114 on the Callisto Sample Prep... ► Artikel lesen | |
ADAPTIMMUNE THERAPEUTICS | 0,206 | -0,96 % | Mizuho downgrades Adaptimmune stock on solvency concerns | ||
CODEXIS | 2,030 | -3,97 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
TELO GENOMICS | 0,080 | +12,77 % | Telo Genomics Corp.: Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma | Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human... ► Artikel lesen |